Skip to main content
S 2554 115th Congress Senate Health Civil actions and liability Drug safety, medical device, and laboratory regulation Health care costs and insurance Health care coverage and access Inflation and prices Prescription drugs

Patient Right to Know Drug Prices Act

Introduced: March 14, 2018 Introduced by: Collins, Susan M. Republican · Maine See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 20 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 10, 2018
Became Public Law No: 115-263.
Oct 10, 2018
Signed by President.
Oct 1, 2018
Presented to President.
Sep 25, 2018
Motion to reconsider laid on the table Agreed to without objection.
Sep 25, 2018
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H8795-8796)
Sep 25, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H8795-8796)
Sep 25, 2018
DEBATE - The House proceeded with forty minutes of debate on S. 2554.
Sep 25, 2018
Considered under suspension of the rules. (consideration: CR H8795-8799)
Sep 25, 2018
Mr. Carter (GA) moved to suspend the rules and pass the bill.
Sep 20, 2018
Held at the desk.
Sep 20, 2018
Received in the House.
Sep 18, 2018
Message on Senate action sent to the House.
Sep 17, 2018
Passed Senate with an amendment by Yea-Nay Vote. 98 - 2. Record Vote Number: 209.
Sep 17, 2018
Passed/agreed to in Senate: Passed Senate with an amendment by Yea-Nay Vote. 98 - 2. Record Vote Number: 209.
Sep 17, 2018
Measure laid before Senate by unanimous consent. (consideration: CR S6179-6180)
Jul 31, 2018
Placed on Senate Legislative Calendar under General Orders. Calendar No. 549.
Jul 31, 2018
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Jul 25, 2018
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Mar 14, 2018
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mar 14, 2018
Introduced in Senate
 Amendments to this bill 1

Amendments propose changes to this bill. Members vote on amendments separately before the final bill vote. An agreed amendment becomes part of the bill; a failed amendment does not.

1 failed

AmendmentSponsorPurposeStatusLatest action
SAMDT 4,011 Lee, Mike To limit application of the gag clause to self-insured group health plans. Failed Sep 17, 2018
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Patient Right to Know Drug Prices Act

(Sec. 2) This bill amends the Public Health Service Act to prohibit a health insurance plan or pharmacy benefits manager from restricting a pharmacy from informing an enrollee of any difference between the out-of-pocket cost of a drug under the plan and the cost of the drug without health insurance coverage. (Such restrictions are commonly referred to as gag clauses.)

(Sec. 3) The bill also amends the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to apply certain antitrust filing requirements for generic drug applicants to biosimilar biological product applicants. (Biosimilar biological products, commonly referred to as biosimilars, are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.) Under current law, generic drug applicants that make agreements with brand name drug companies or other generic drug applicants regarding the manufacture, marketing, or sale of their drugs must file such agreements with the Federal Trade Commission and the Department of Justice. The bill subjects biosimilar biological product applicants to the same filing requirements.

What's happening now October 10, 2018

Became Public Law No: 115-263.

 Related & companion bills 3
  • HR 6733 Related bill Know the Cost Act of 2018
  • S 2553 Related bill Know the Lowest Price Act of 2018
  • HR 6143 Identical bill Patient Right to Know Drug Prices Act
 Bill text 5 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 16
All 16 Democratic 6 Republican 9 Independent 1
R
Grassley, Chuck
Iowa · Sep 17, 2018
 D
Klobuchar, Amy
Minnesota · Sep 17, 2018
 D
Heinrich, Martin
New Mexico · Sep 12, 2018
 I
King, Angus S., Jr.
Maine · Sep 6, 2018
 R
Boozman, John
Arkansas · Aug 27, 2018
 R
Fischer, Deb
Nebraska · Aug 15, 2018
 R
Capito, Shelley Moore
West Virginia · Aug 1, 2018
 R
Wicker, Roger F.
Mississippi · Aug 1, 2018
 D
Blumenthal, Richard
Connecticut · Jul 30, 2018
 D
Hassan, Margaret Wood
New Hampshire · Jul 25, 2018
 R
Kennedy, John
Louisiana · Jul 25, 2018
 D
Baldwin, Tammy
Wisconsin · Jul 24, 2018
 R
Murkowski, Lisa
Alaska · Jul 19, 2018
 D
Smith, Tina
Minnesota · Jun 7, 2018
 R
Barrasso, John
Wyoming · Mar 14, 2018
 R
Cassidy, Bill
Louisiana · Mar 14, 2018
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2554: Patient Right to Know Drug Prices Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-2554/
MLA
"S. 2554: Patient Right to Know Drug Prices Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-2554/.
Bluebook (legal)
S. 2554, 115th Cong. (2026), https://openamerica.io/bill/115-S-2554/.
Markdown link
[S. 2554: Patient Right to Know Drug Prices Act](https://openamerica.io/bill/115-S-2554/)
Report a problem